Time filter

Source Type

This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.


Patent
Aventis Pharmaceuticals | Date: 2012-04-18

The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R_(1), R_(2), R_(3 )and R_(4 )are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.


This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.


Patent
Aventis Pharmaceuticals | Date: 2011-12-14

The present invention relates to novel and useful methods that predict or monitor a patients response to a molecule of the taxoid family by measuring the increase or decrease of specific genetic markers, in particular STK11, as compared to controls. The present invention also provides kits that predict of monitor patients response to a molecule of the taxoid family by measuring nucleic acid or protein levels of particular genetic markers and comparing their levels to controls or reference markers.


Patent
Aventis Pharmaceuticals | Date: 2011-06-10

The present invention is directed to nuclear factor B (NFB)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NFB. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NFB induction in a patient, methods and compositions for lowering NFB induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NFB-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.


Patent
Aventis Pharmaceuticals | Date: 2013-11-18

The present invention relates to a pharmaceutical formulation of fexofenadine hydrochloride in a solvent system suitable as a liquid fill composition. In another aspect, the invention also relates to a process for the preparation of the pharmaceutical formulation and the use of the composition for the treatment of allergic reactions in a patient.


Patent
Aventis Pharmaceuticals | Date: 2011-05-31

An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the nasal cavity; and (B) a suspending agent in an amount effective to maintain said particles dispersed uniformly in the composition and to impart to the composition the following thixotropic properties: (i) the viscosity of the position in unsheared form is relatively high, with the composition being in gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (D) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively high and such that it resists being cleared from the mucosal surfaces by the inherent mucocillary forces which are present in the nasal cavity, a method of use of the composition and a method for preparation of the composition, including in preferred form the use of anti-inflammatory steroid, for example, triamcinoline acetonide, and an odorless form of the composition.


Patent
Aventis Pharmaceuticals | Date: 2012-04-24

The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R_(1), P_(1), P_(2 )and P_(3 )are as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.


Patent
Aventis Pharmaceuticals | Date: 2012-09-11

The present invention is directed to a substituted pyrimidine compound of formula (I) or an enantiomer thereof, or a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound.


Patent
Aventis Pharmaceuticals | Date: 2012-09-11

The present invention is directed to a 2,6-substituted-4-monosubstitutedamino-pyrimidine compound of formula (I): or an enantiomer thereof, or an ester prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound.

Loading Aventis Pharmaceuticals collaborators
Loading Aventis Pharmaceuticals collaborators